Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toni K. Choueiri, M.D.

Co-Author

This page shows the publications co-authored by Toni Choueiri and Bradley McGregor.
Connection Strength

6.325
  1. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849.
    View in: PubMed
    Score: 0.940
  2. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020 08; 135:203-210.
    View in: PubMed
    Score: 0.914
  3. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020 12; 38(6):1807-1814.
    View in: PubMed
    Score: 0.909
  4. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.876
  5. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.241
  6. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.239
  7. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020 12 20; 38(36):4240-4248.
    View in: PubMed
    Score: 0.234
  8. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol. 2020 10 01; 6(10):1606-1610.
    View in: PubMed
    Score: 0.233
  9. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2020 06; 3(3):372-381.
    View in: PubMed
    Score: 0.217
  10. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res. 2018 04; 6(4):402-408.
    View in: PubMed
    Score: 0.194
  11. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5.
    View in: PubMed
    Score: 0.193
  12. JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncol. 2018 01; 19(1):5-7.
    View in: PubMed
    Score: 0.191
  13. Immunotherapy in the Elderly. Eur Urol Focus. 2017 10; 3(4-5):403-412.
    View in: PubMed
    Score: 0.191
  14. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017 10; 72(4):557-564.
    View in: PubMed
    Score: 0.183
  15. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Sep 07; JCO2100939.
    View in: PubMed
    Score: 0.062
  16. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Sep 02; 157:50-58.
    View in: PubMed
    Score: 0.062
  17. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):649-661.e5.
    View in: PubMed
    Score: 0.060
  18. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.060
  19. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.059
  20. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.056
  21. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020 02; 8(1).
    View in: PubMed
    Score: 0.056
  22. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
    View in: PubMed
    Score: 0.055
  23. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. Eur Urol. 2019 01; 75(1):100-110.
    View in: PubMed
    Score: 0.051
  24. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.